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Abstract
Background: ROCKET AF and its East Asian subanalysis demonstrated that rivaroxaban
was non-inferior to warfarin for stroke/systemic embolism (SE) prevention in patients
with non-valvular atrial fibrillation (NVAF), with a favorable benefit–risk profile. XANAP
investigated the safety and effectiveness of rivaroxaban in routine care in Asia-Pacific.
Methods: XANAP was a prospective, real-world, observational study in patients with
NVAF newly starting rivaroxaban. Patients were followed at ~3-month intervals for
1 year, or for ≥30 days after permanent discontinuation. Primary outcomes were
major bleeding events, adverse events (AEs), serious AEs and all-cause mortality; sec-
ondary outcomes included stroke/SE. Major outcomes were adjudicated centrally.
Results: XANAP enrolled 2273 patients from 10 countries: mean age was
70.5 years and 58.1% were male. 49.8% of patients received rivaroxaban 20 mg
once daily (od), 43.8% 15 mg od and 5.9% 10 mg od. Mean treatment duration was
296 days, and 72.8% of patients had received prior anticoagulation therapy. Co-
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morbidities included heart failure (20.1%), hypertension (73.6%), diabetes mellitus
(26.6%), prior stroke/non-central nervous system SE/transient ischemic attack
(32.8%) and myocardial infarction (3.8%). Mean CHADS2, CHA2DS2-VASc and HAS-
BLED scores were 2.3, 3.7 and 2.1, respectively. The rates (events/100 patient-
years [95% confidence interval]) of treatment-emergent major bleeding, stroke and
all-cause mortality were 1.5 (1.0-2.1), 1.7 (1.2-2.5) and 2.0 (1.4-2.7), respectively.
Persistence was 66.2% at the study end.
Conclusions: The real-world XANAP study demonstrated low rates of stroke and
bleeding in rivaroxaban-treated patients with NVAF from Asia-Pacific. The results
were consistent with the real-world XANTUS study and ROCKET AF.
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1 | INTRODUCTION
The prevalence of non-valvular atrial fibrillation (NVAF) is growing
rapidly in Asia, and it is estimated that the number of patients with
NVAF in Asia will be greater than the number in Europe and the
USA combined by 2050.1 Data from large clinical trials have clearly
indicated differences in the benefit–risk profiles of Asian and Cau-
casian patients, particularly a higher overall risk of stroke, and
greater stroke-related morbidity and mortality in Asian patients.2–4
Although treatment with vitamin K antagonists (VKAs) has long been
the mainstay of therapy in this setting, warfarin is under-prescribed
in Asian countries; antiplatelet therapy is commonly prescribed
instead.4 As an alternative to VKAs, non-VKA oral anticoagulants
(NOACs) could be prescribed in Asian patients with NVAF. The
phase III ROCKET AF study showed that rivaroxaban was non-infer-
ior to warfarin for stroke prevention in patients with NVAF, with a
reduced incidence of hemorrhagic stroke and ICH compared with
warfarin.5 A subgroup analysis in East Asian patients showed similar
efficacy and safety of rivaroxaban vs warfarin,6 as did J-ROCKET AF,
which assessed reduced-dose rivaroxaban (15 mg once daily [od]) in
Japanese patients with NVAF.7 In 2013, the Asia Pacific Heart
Rhythm Society (APHRS) added recommendations for the use of
NOACs in patients with NVAF.8
Real-world evidence is increasingly being recognized as an
essential component of the clinical evidence base, to complement
phase III data in unselected patient populations and provide addi-
tional safety information after approval of new drugs. The
prospective, observational XANTUS study investigated the safety
and effectiveness of rivaroxaban in patients with NVAF in routine
clinical practice in Europe, Israel and Canada.9 The results demon-
strated low rates of bleeding and stroke/non-central nervous sys-
tem (CNS) systemic embolism (SE) in a broad, unselected patient
population with NVAF.
Xarelto for Prevention of Stroke in Patients With Atrial Fibrilla-
tion in Asia (XANAP) was a sister study to XANTUS and enrolled
patients from the Asia-Pacific region. The main goal of this
observational study was to investigate the safety of rivaroxaban use
in clinical practice, thereby providing data under real-life conditions.
2 | METHODS
XANAP was a prospective, observational cohort study in unselected
patients with NVAF starting rivaroxaban treatment to prevent stroke
or non-CNS SE. The study was part of the XANTUS program and, as
such, the study protocol was aligned with that of XANTUS, which is
published elsewhere.10
2.1 | Study population and data collection
All study sites were in 10 countries across the Asia-Pacific region: Hong
Kong, Indonesia, Malaysia, Pakistan, Philippines, Singapore, South
Korea, Taiwan, Thailand and Vietnam. Eligible patients were adults
(aged ≥18 years) with a diagnosis of NVAF who provided written
informed consent to participate in the study and who started rivaroxa-
ban treatment for the prevention of stroke or non-CNS SE in accor-
dance with the country-specific drug approval. Participating
investigators were asked to screen all patients with NVAF receiving
pharmacological treatment for stroke prevention regardless of the pre-
scribed treatment. This screening documentation occurred before eligi-
ble and consenting patients signed the informed consent forms and it
was not permissible to collect any patient-related data from the remain-
ing patients. Each patient was consecutively screened and documented
in an anonymous patient log file. To reduce selection bias, enrollment
was consecutive and no eligible patients were to be omitted.
2.2 | Medication and follow-up
The decision to treat with rivaroxaban was solely at the discretion of
the treating physician. Label-recommended doses were prescribed in
accordance with the country-specific drug approval. In Taiwan, the
approved rivaroxaban dose is 15 or 20 mg od for patients with
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creatinine clearance (CrCl) >50 mL/min, and 10 or 15 mg od for
patients with CrCl 15-50 mL/min.11 The approved doses of rivaroxa-
ban in the other countries are similar to European label recommen-
dations, ie, 20 mg od for patients with CrCl ≥50 mL/min and 15 mg
od for patients with CrCl 15-49 mL/min.12 Patients were followed
up for 1 year or until 30 days after permanent discontinuation of
rivaroxaban (if <1 year) and investigators were asked to collect data
at approximately 3-month intervals.
2.3 | Study outcomes
The primary outcomes were related to the safety of rivaroxaban and
recorded as treatment-emergent adverse events (AEs), serious AEs
(SAEs), all-cause mortality and major bleeding events (defined using
International Society on Thrombosis and Haemostasis criteria). Sec-
ondary outcomes were symptomatic thromboembolic events, non-
major bleeding, treatment satisfaction, healthcare resource (number
of healthcare professional visits and hospitalizations), treatment per-
sistence and AE/SAE rates in different NVAF risk factor categories.
A Central Adjudication Committee adjudicated the endpoints of
major bleeding events, stroke, transient ischemic attack (TIA), non-
CNS SE, myocardial infarction (MI), pulmonary embolism, deep vein
thrombosis, atrial thrombus, and all-cause death.
2.4 | Study governance
The study complied with the Declaration of Helsinki and was
approved by the appropriate Health Authorities, the independent
Ethics Committees and independent Review Boards as required. The
study was conducted in accordance with Good Pharmacoepidemio-
logical Practice. An independent academic steering committee over-
saw the design, execution and conduct of the study; was responsible
for manuscript development; had full access to all of the data; and
approved all versions of the manuscript.
Data management and statistical analyses were overseen by the
sponsor to keep within Good Clinical Practice standards. The lead statis-
tician oversaw programming and validation of the statistical analyses.
2.5 | Statistical analysis
Descriptive statistical analyses were performed on the safety popula-
tion, which included all patients who took at least 1 dose of rivarox-
aban. Events were considered treatment-emergent if they occurred
on or after the first dose of rivaroxaban and up to 2 days after the
last dose. Statistical analyses were explorative and descriptive in nat-
ure. Incidence proportions (number of patients with events/number
of treated patients) and incidence rates (events per 100 patient-
years) are presented with corresponding Pearson–Clopper and Pois-
son rate 95% confidence intervals (CIs), respectively.
3 | RESULTS
3.1 | Patient population
A total of 2910 patients were screened between January 2013 and
October 2015; 2273 were enrolled in the study. The main reasons for
Screened
(N = 2910)
Enrolled
(N = 2273)
Rivaroxaban 20 mg od
(n = 1133, 49.8%)
Reason patient not included in study
Major events, specifically 
major bleeding, stroke, SE, 
TIA, MI and all-cause death, 
adjudicated centrally by an 
independent CAC
Primary analysis population: 
defined as all patients who 
had taken at least one dose 
of rivaroxaban 
Patient decision (n = 235, 8.1%)
Administrative reason (n = 6, 0.2%)
Availability of drug (n = 111, 3.8%)
Medical guidelines (n = 18, 0.6%)
Price of drug (n = 23, 0.8%)
Medical reasons (n = 26, 0.9%)
Internal hospital guidelines (n = 0)
Type of health insurance (n = 22, 0.8%)
Other (n = 233, 8.0%)
Safety population
(N = 2273)
Rivaroxaban 15 mg od 
(n = 995, 43.8%)
Rivaroxaban 10 mg od 
(n = 133, 5.9%)
Another dose
(n = 12, 0.5%)
F IGURE 1 Patient disposition. CAC, Central Adjudication Committee; MI, myocardial infarction; od, once daily; SE, systemic embolism; TIA,
transient ischemic attack
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exclusion were because of patient decision (n = 235) and availability of
drug (n = 111). All enrolled patients were included in the XANAP safety
population (Figure 1). The largest patient populations were from South
Korea (844 [37.1%]) and Taiwan (614 [27.0%]). The 8 remaining countries
each contributed <10% to the study population. The mean treatment
duration (standard deviation) was 296 days (129), with most patients
(71%) treated with rivaroxaban for >270 days. Persistence with treat-
ment was 66.2% at the end of the study.
The baseline demographics and clinical characteristics of these
patients are shown in Table 1. Of note, the proportion of patients who
had received prior anticoagulation therapy was high (72.8%), with
35.9% having received prior VKA monotherapy. Mean patient age was
70.5 years; 40.0% of all patients were aged ≥75 years and 58.1% were
male. Overall, 49.8% of patients received an initial rivaroxaban dose of
20 mg od; 43.8% and 5.9% received an initial 15 mg od and 10 mg od
dose, respectively (Figure 1). Approximately half (48.5%) of patients
had missing CrCl data. Of those patients with reported data, 55.0% of
patients with a CrCl ≤49 mL/min received rivaroxaban 15 mg od. In
patients with a CrCl ≥50 mL/min, rivaroxaban 20 mg od was the most
commonly used dose (in 57.4% of patients; Figure S1). Patients had a
mean CHADS2 score of 2.3, a mean CHA2DS2-VASc score of 3.7 and
a mean HAS-BLED score of 2.1. In total, 10.9% of patients had a
CHA2DS2-VASc score of 0 or 1. Co-morbidities were as follows: 456/
2273 (20.1%) patients had congestive heart failure, 1673 (73.6%) had
hypertension, 605 (26.6%) diabetes mellitus, 746 (32.8%) prior stroke/
non-CNS SE/TIA and 86 (3.8%) prior MI. There were 504/2273
(22.2%) patients with a first diagnosis of non-valvular AF, 693 (30.5%)
with paroxysmal AF, 576 (25.3%) with persistent AF and 477 (21.0%)
with permanent AF.
3.2 | Outcomes
Overall, 1.2% (95% CI 0.8-1.7) of the cohort of 2273 patients had
adjudicated treatment-emergent major bleeding events (primary
TABLE 1 Baseline demographics and clinical characteristics of
patients in XANAP
Rivaroxaban
(N = 2273)
Age, y, mean  SD 70.5  10.6
<75 y, n (%) 1364 (60.0)
≥75 y, n (%) 909 (40.0)
Gender, male, n (%) 1320 (58.1)
Weight, kg, mean  SD 66.1  12.8
BMI, kg/m2, mean  SD 25.0  4.0
First available CrCl (mL/min), n (%)
<15 15 (0.7)
≥15-<30 55 (2.4)
≥30-<50 301 (13.2)
≥50-≤80 543 (23.9)
>80 257 (11.3)
Missing 1102 (48.5)
Existing co-morbidities, n (%)
Congestive heart failure 456 (20.1)
Hypertension 1673 (73.6)
Diabetes mellitus 605 (26.6)
Prior stroke/non-CNS SE/TIA, n (%) 746 (32.8)
Prior MI 86 (3.8)
AF type, n (%)
First diagnosed 504 (22.2)
Paroxysmal 693 (30.5)
Persistent 576 (25.3)
Permanent 477 (21.0)
Missing 23 (1.0)
CHADS2 score, mean  SD 2.3  1.3
CHA2DS2-VASc score, mean  SD 3.7  1.8
HAS-BLED score, mean  SD 2.1  1.2
Prior antithrombotic therapy, n (%)
Yes 1449 (63.7)
VKA 813 (35.8)
Direct thrombin inhibitor 149 (6.6)
Acetylsalicylic acid 364 (16.0)
Dual antiplatelet therapy 24 (1.1)
Factor Xa inhibitor (excluding rivaroxaban) 1 (<0.05)
Other 19 (0.8)
Multiple 69 (3.0)
AF, atrial fibrillation; BMI, body mass index; CNS, central nervous system;
CrCl, creatinine clearance; MI, myocardial infarction; SD, standard devia-
tion; SE, systemic embolism; TIA, transient ischemic attack; VKA, vitamin
K antagonist.
TABLE 2 Summary of causes of adjudicated treatment-emergent
deaths
Adjudicated causes of death,a n (%) Deaths (N = 36)
Bleeding 4 (11.1)
Extracranial hemorrhage 1 (2.8)
Intracranial bleeding 3 (8.3)
Cancer 0
Cardiovascular 21 (58.3)
Cardiac decompensation, heart failure 7 (19.4)
Arrhythmia 0
MI 0
Non-hemorrhagic stroke 3 (8.3)
Sudden or unwitnessed death 8 (22.2)
Venous thromboembolism 1 (2.8)
Other vascular events 2 (5.6)
SE 0
Infectious disease 7 (19.4)
Other 3 (8.3)
Unexplained 6 (16.7)
MI, myocardial infarction; SE, systemic embolism.
aMultiple reasons were recorded for the cause of adjudicated treatment-
emergent death of some patients.
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outcome), and the incidence rate was 1.5 events/100 patient-years
(95% CI 1.0-2.1). There were 4 fatalities (incidence rate: 0.2 events/
100 patient-years; 95% CI 0.1-0.6) from adjudicated treatment-
emergent major bleeding events. Incidence rates were 0.7 events/
100 patient-years (95% CI 0.4-1.2) for ICH and 0.5 events/100
patient-years (95% CI 0.2-0.9) for gastrointestinal (GI) bleeding. Any
treatment-emergent AEs and SAEs (primary outcome) occurred in
763/2273 (33.6%) and 272/2273 (12.0%) patients, respectively, with
corresponding incidence rates of 50.3 events/100 patient-years
(95% CI 46.8-54.0) and 15.6 events/100 patient-years (95% CI 13.8-
17.5), respectively. Causes of adjudicated treatment-emergent deaths
(primary outcome) are presented in Table 2. All-cause death
occurred in 36 patients (1.6%), with cardiovascular death being the
most common adjudicated cause of death (21 patients [58.3%],
including 3 patients [8.3%] who died from non-hemorrhagic stroke).
Forty-seven patients had adjudicated treatment-emergent symp-
tomatic thromboembolic events (secondary outcome) and the
incidence rate was 2.6 events/100 patient-years (95% CI 1.9-3.4).
The incidence rates (number of events/100 patient-years [95% CI])
for stroke (any), TIA, non-CNS SE, stroke/non-CNS SE and MI were
1.7 (1.2-2.5), 0.2 (0.1-0.6), 0.1 (0.0-0.4), 1.9 (1.3-2.6) and 0.5 (0.2-
0.9), respectively (Table 3).
Rates of major bleeding events and stroke/non-CNS SE generally
rose with increasing CHADS2 and CHA2DS2-VASc scores (Figure 2A,
B). No major bleeding events were recorded for patients with a
CHA2DS2-VASc score of 0 or 1, compared with an incidence rate of
1.6 events/100 patient-years (95% CI 1.1-2.4) in patients with a
score of ≥2. Similarly, there were no recorded incidents of stroke/
non-CNS SE in patients with a CHA2DS2-VASc score of 0 or 1, rising
to an incidence rate of 0.7 events/100 patient-years (95% CI 0.1-
2.6) in patients with a score of 2, and 3.3 events/100 patient-years
(95% CI 1.6-6.1) in patients with scores of 6-9. The incidence of
major bleeding increased with age, occurring at a rate of 1.1 events/
100 patient-years (95% CI 0.6-1.9) in patients aged <75 years and
TABLE 3 Adjudicated treatment-emergent thromboembolic and
bleeding events and all-cause death
Incidence
proportion, %
of patients
(95% CI)
Incidence rate, number
of patients/100
patient-years (95% CI)
Major bleeding 1.2 (0.8-1.7) 1.5 (1.0-2.1)
Fatal 0.2 (0.0-0.4) 0.2 (0.1-0.6)
Bleeding at a critical site 0.6 (0.3-1.0) 0.8 (0.4-1.3)
Intracranial hemorrhage 0.6 0.7 (0.4-1.2)
GI 0.4 (0.2-0.8) 0.5 (0.2-0.9)
Non-major bleeding events 8.8 (7.6-10.0) 11.2 (9.7-12.9)
Thromboembolic events
(stroke, TIA, non-CNS
SE and MI)
2.1 (1.5-2.7) 2.6 (1.9-3.4)
Stroke/non-CNS SE 1.5 (1.0-2.1) 1.9 (1.3-2.6)
Stroke 1.4 (1.0-2.0) 1.7 (1.2-2.5)
Primary hemorrhagic 0.4 NA
Primary ischemic 0.9 NA
Hemorrhagic
transformation
0.1 NA
No hemorrhagic
transformation
0.8 NA
Missing 0 NA
Non-CNS SE 0.1 (0.0-0.3) 0.1 (0.0-0.4)
TIA 0.2 (0.0-0.4) 0.2 (0.1-0.6)
MI 0.4 (0.2-0.8) 0.5 (0.2-0.9)
Composite endpoint
(stroke/non-CNS SE,
major bleeding and
all-cause death)
3.4 (2.7-4.2) 4.2 (3.3-5.2)
All-cause death 1.6 (1.1-2.2) 2.0 (1.4-2.7)
CI, confidence interval; CNS, central nervous system; GI, gastrointestinal;
MI, myocardial infarction; NA, not available; SE, systemic embolism; TIA,
transient ischemic attack.
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F IGURE 2 A, Incidence proportion of adjudicated treatment-
emergent stroke/non-CNS SE and major bleeding by CHADS2 score;
B, Incidence proportion of adjudicated treatment-emergent stroke/
non-CNS SE and major bleeding by CHA2DS2-VASc score. CNS,
central nervous system; SE, systemic embolism
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2.1 events/100 patient-years (95% CI 1.2-3.4) in patients aged
≥75 years. The corresponding rates for stroke/non-CNS SE were 1.6
events/100 patient-years (95% CI 1.0-2.6) and 2.2 events/100
patient-years (95% CI 1.3-3.6).
The cumulative number of adjudicated treatment-emergent major
bleeding events, deaths and symptomatic thromboembolic events
increased gradually with time on treatment (Figure 3). Overall, very
few patients experienced adjudicated treatment-emergent major
bleeding, death, stroke or non-CNS SE (4.2 events/100 patient-years
[95% CI 3.3-5.2]). The incidence rates (number of events/100
patient-years [95% CI]) of adjudicated treatment-emergent major
bleeding and death were small but numerically higher for patients
receiving rivaroxaban 15 mg od compared with those receiving
rivaroxaban 20 mg od (1.5 [0.8-2.6] vs 1.1 [0.5-2.0] and 2.2 [1.3-3.5]
vs 1.5 [0.8-2.6], respectively [Figure S2]). Rates of treatment-emer-
gent outcomes by renal function, and by renal function and dose in
patients receiving rivaroxaban 15 mg od or 20 mg od, are shown in
Figures S3 and S4, respectively. The endpoints of adjudicated treat-
ment-emergent thromboembolic, and bleeding events and all-cause
death are detailed in Table 3.
3.3 | Additional outcomes
In total, 116 patients (5.1%) had at least 1 interruption to rivaroxa-
ban treatment, which was most commonly due to bleeding (31
patients) or surgery (26 patients). The median treatment interruption
was 7 days (interquartile range: 3-23 days). The majority of patients
(83.2%) had no unscheduled hospital or general practitioner visits
because of the use of rivaroxaban. The majority of patients (60.6%)
reported to their physicians that they were either “very satisfied” or
“satisfied” with rivaroxaban treatment; a further 26.1% of patients
were “neutral”, 6.9% were “unsatisfied”, 0.8% were “very unsatisfied”
and data were missing for 5.5%.
4 | DISCUSSION
The XANAP study provides insights into the routine clinical use of
rivaroxaban in Asian patients with NVAF. XANAP is the first
prospective, observational study to describe rivaroxaban use in a
broad, real-world patient population with NVAF in 10 countries of
the Asia-Pacific region. Findings are broadly consistent when cau-
tiously compared with those of the observational sister study (XAN-
TUS) in Europe, Canada and Israel,9 and with the subanalysis of East
Asian patients in the phase III ROCKET AF study,6 taking into con-
sideration differences in baseline characteristics. In XANAP, rivaroxa-
ban demonstrated relatively low rates of stroke/non-CNS SE and
low rates of major bleeding, including intracranial and GI bleeding.
Over 96% of patients with a mean CHADS2 score of 2.3 receiving
rivaroxaban did not experience any of the outcomes of stroke/non-
CNS SE, treatment-emergent major bleeding or all-cause death.
The profile of the patient population in XANAP was substantially
different from that in XANTUS (Table 4).9 Differences included a
higher proportion of patients with prior stroke/non-CNS SE/TIA,
lower mean weight (although weight data were unavailable for 28%
of XANAP patients), a higher proportion of patients with moderate
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Time to event (days)
2273 2170 2076 2002 1906 1844 1773 1715 1674 1617 1535 1385 970 361 166
2273 2170 2076 2001 1904 1845 1773 1713 1672 1614 1530 1379 969 361 166
Patients at risk:
Major bleeding event
All-cause death
Symptomatic thromboembolic event
F IGURE 3 Cumulative rates (Kaplan–Meier) for adjudicated treatment-emergent all-cause death, major bleeding events and symptomatic
thromboembolic events
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or severe renal impairment (with the caveat that CrCl data were not
reported for approximately half [48.5%] of patients in XANAP and
approximately one-third [34.4%] of patients in XANTUS) and slightly
higher mean CHADS2, CHA2DS2-VASc and HAS-BLED scores. These
scores were originally derived from Caucasian populations to calcu-
late stroke and bleeding risk in patients with NVAF; however, they
have also been shown to be predictive of future stroke and bleeding
risk in some Asian populations.4 Based on these scores, NVAF can
be calculated to raise the relative risk of stroke fivefold in Caucasian
populations, compared with a more modest increase in risk of 2.8-
3.7-fold, depending on the Asian population studied.4 Finally, persis-
tence at 1 year was lower in XANAP compared with XANTUS (66%
vs 80%; Table 4). It is of note that this result is consistent with the
treatment persistence reported in a recent large retrospective data-
base analysis of US patients treated with rivaroxaban for stroke pre-
vention (N = 10 878; 60.1% persistence to rivaroxaban therapy at
1 year).13 However, it should be pointed out that the US patient
population in this analysis was enrolled in a different healthcare sys-
tem to those countries in the XANAP studies.13 The lower persis-
tence in XANAP vs XANTUS may reflect lower medication
adherence in developing countries, which were highly represented in
XANAP.14 Other reasons for the lower persistence rate in XANAP
may include issues related to reimbursement, or a lack of follow-up
provision of prescriptions from general practitioners after an initial
TABLE 4 XANAP results in the context of similar clinical trials in different patient populations with atrial fibrillation
ROCKET AF
globala,b 5,24 (N = 7131)c
J-ROCKET
AFb,d 7 (N = 639)e
ROCKET AF
East Asiaa,b 6 (N = 468)f
XANTUSa,g 9
(N = 6784)
XANAPa,g
(N = 2273)
Baseline characteristics
Age, y, mean 73h 71 70 71.5 70.5
Weight, kg, mean – – 67.3 83 66
CrCl <50 mL/min, % 20.7i 22 – 9.4 16.3
Congestive heart failure, % 63 41 39 19 20
Hypertension, % 90 80 79 75 74
Diabetes, % 40 39 38 20 27
Prior stroke/SE/TIA, % 55 64 65 19 33
Mean CHADS2 score 3.5 3.3 3.2 2.0 2.3
Mean CHA2DS2-VASc score – – 4.4 3.4 3.7
Mean HAS-BLED score 2.8j – 2.9 2.0 2.1
Use of rivaroxaban
15 mg od dose, %
20.7i – – 21 44 (+6% 10 mg)
Major outcomes (events/100 patient-years)
Major bleeding 3.6 3.0 3.4 2.1 1.5
Fatal 0.2 0.1 0.2 0.2 0.2
In critical organ 0.8 1.5 0.7 0.7 0.8
ICH 0.5 0.8%k 0.6 0.4 0.7
GI 2.0l 1.3%k – 0.9 0.5
Stroke/SE 1.7 1.3 2.6 0.8 1.9
Stroke 1.7 1.6%k 2.6 0.7 1.7
Ischemic 1.3 1.1%k 2.1 0.5k 0.9%k
Hemorrhagic 0.3 0.5%k 0.5 0.2k 0.4%k
SE <0.1 0.2%k 0 0.1 0.1
MI 0.9 0.5%k 1.0 0.4 0.5
Thromboembolism
(stroke, SE, TIA, MI)
– – – 1.8 2.6
All-cause death 1.9 1.1%k 2.6 1.9 2.0
Hemoglobin drop 2.8 1.5 3 0.9 0.1
Transfusions 1.6 0.5 1.2 0.9 0.6
All bleeding – – – ~17.5 ~12.7
Major bleeding +
clinically relevant
non-major bleeding
15 18 21 – –
(Continues)
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hospital prescription. Taken together, these differences indicate that
the Asian population in XANAP was at higher risk of stroke and
bleeding than the European and Canadian population in XANTUS,
which is consistent with the observed higher incidence of hemor-
rhagic stroke and ICH in Asian patients.4 Further comparisons show
that XANAP patients were at lower risk of these outcomes than
patients in the ROCKET AF East Asian subanalysis6 and J-ROCKET,7
with CHADS2 scores of 2.3 vs 3.2 and 3.3, respectively (CHA2DS2-
VASc score of 3.7 in XANAP, vs 4.4 in the ROCKET AF East Asian
subanalysis; Table 4).
Overall rates of major bleeding, including major GI bleeding,
were lower in patients in XANAP than observed in XANTUS, the
ROCKET AF East Asian subanalysis and J-ROCKET (Table 4).6,9 The
reason for the lower rates of bleeding in XANAP is not completely
understood. It is unlikely to simply be a result of the higher propor-
tion of patients in XANAP receiving rivaroxaban 15 mg od, as the
findings are consistent with the lower overall bleeding rates
observed in rivaroxaban-treated patients in ROCKET AF from East
Asia6 and China,15 compared with patients outside these regions.
However, rates of ICH were higher in XANAP compared with XAN-
TUS, but similar to those in the ROCKET AF East Asian subanalysis.
This concurs with previously observed higher rates of ICH in Asian
populations,16,17 which are thought to be because of increased
cerebral microbleeds in Asian patients4 and can be affected by
extremes in body mass index and specific apolipoprotein alleles.16
By contrast, fatal bleeding rates in XANAP were similar to those in
XANTUS, the ROCKET AF East Asian subanalysis and J-ROCKET
(Table 4).6,9
The rates of stroke/non-CNS SE in XANAP were higher than
those in XANTUS, but lower than those observed in the ROCKET
AF East Asian subanalysis; this was consistent with the higher stroke
risk and proportion of patients with prior stroke/SE/TIA involved in
the ROCKET AF East Asian subanalysis (65%, vs 19% in XANAP;
Table 4). Stroke is noted in the literature as being a particular risk
for Asian patients with NVAF compared with their Caucasian coun-
terparts.4,18–20 This is consistent with the higher proportion of
patients with prior stroke/non-CNS SE/TIA at baseline in XANAP
(33%, vs 19% in XANTUS). It is possible that this apparently inherent
higher risk of stroke in Asian populations contributed to the higher
rate of stroke/non-CNS SE in XANAP. In addition, a potential effect
of the ~twofold higher proportion of patients receiving the rivaroxa-
ban 15 mg od dose on increased stroke/SE rates in XANAP cannot
be completely excluded. However, it is unclear to what extent the
higher proportion of patients receiving the reduced dose would rep-
resent inappropriate dosing, as there was a large proportion (48.5%)
of patients with unreported CrCl data in XANAP. Additionally, regio-
nal differences in the Taiwan label (27% of the XANAP population:
recommended dose of rivaroxaban 15 or 20 mg od in patients with
CrCl >50 mL/min and rivaroxaban 10 or 15 mg od in patients with
CrCl 15-50 mL/min11) mean that the majority of the Taiwanese
patients with CrCl ≥50 mL/min receiving the 15 mg dose were on
label. It is also possible that physicians prescribed reduced rivaroxa-
ban 15 mg od to patients with a higher co-morbidity burden who
were more at risk of AEs; in XANTUS, rates of major outcomes were
worse in patients receiving the reduced rivaroxaban dose.9 However,
it is also of note that the rivaroxaban 15 mg od dose was not
TABLE 4 (Continued)
ROCKET AF
globala,b 5,24 (N = 7131)c
J-ROCKET
AFb,d 7 (N = 639)e
ROCKET AF
East Asiaa,b 6 (N = 468)f
XANTUSa,g 9
(N = 6784)
XANAPa,g
(N = 2273)
Unknown type of stroke 0.1 0 0.1m 0 0.2%k
AE 81%k – – 40 50.3
SAE – 24%k 23.2%k 18 15.6
1-y persistence, % – – – 80 66
AE, adverse event; CrCl, creatinine clearance; GI, gastrointestinal; ICH, intracranial hemorrhage; MI, myocardial infarction; od, once daily; SAE, serious
adverse event; SE, systemic embolism; TIA, transient ischemic attack.
aThe rivaroxaban dose was 20 mg od, with the ROCKET AF, ROCKET AF East Asian subanalysis, XANTUS and XANAP studies also having a rivaroxaban
15 mg od dose in patients with renal impairment (30-49 mL/min in ROCKET AF and East Asian subanalysis; 15-49 mL/min in XANTUS and XANAP).
bThe primary outcome for ROCKET AF, ROCKET AF East Asian subanalysis and J-ROCKET AF was the composite of stroke (ischemic and hemorrhagic)
and SE.
cBleeding outcomes in the safety population (n = 7111), efficacy outcomes in the safety, on-treatment population, which excluded 1 site for violation of
Good Clinical Practice (n = 7061).
dThe rivaroxaban dose was 15 mg od in J-ROCKET AF, with a rivaroxaban 10 mg od dose in patients with renal impairment (CrCl 30-49 mL/min).
eBleeding outcomes in the safety, on-treatment population (n = 639), efficacy outcomes in the per protocol, on treatment population (n = 637).
fBleeding outcomes in the safety, on-treatment population (n = 466), efficacy outcomes in the intention-to-treat population (n = 468).
gThe primary outcomes for XANTUS and XANAP were related to the safety of rivaroxaban and recorded as treatment-emergent AEs and SAEs, all-cause
mortality and major bleeding events (defined using International Society on Thrombosis and Haemostasis criteria).
hMedian age.
iReported in Fox et al.25
jReported in Breithardt et al.26
kIncidence proportion.
lReported in Sherwood et al.24
mIn intention-to-treat population.
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associated with higher stroke/SE rates than warfarin in Japanese
patients enrolled in the J-ROCKET AF trial or in patients included in
a large retrospective Danish registry analysis.21,22 Another possible
contributor to the higher stroke/SE rate in XANAP was the lower
rate of persistence observed in XANAP compared with XANTUS
(66% vs 80%), because breaks in anticoagulation could leave patients
with NVAF at higher risk of stroke. Of note, the incidence rate of
stroke/non-CNS SE in XANAP of 1.9 events/100 patient-years is
lower than that reported in a recent retrospective cohort study of
Taiwanese patients with NVAF; the annual rate in patients taking
rivaroxaban (N = 3916) was 3.07 events/100 patient-years (95% CI
2.12-4.02) vs 5.62 events/100 patient-years (95% CI 4.48-6.76) in
those receiving warfarin (N = 5251).23 However, caution must be
exercised in comparing data from a retrospective database with the
observational study presented here.
Unlike XANTUS, where cancer was one of the main adjudicated
causes of death in 19.5% of the patients who died,9 the number of
patients with active cancer at baseline, and consequently of
patients who died of cancer, was much lower in XANAP than in
XANTUS. This may explain why the proportion of cardiovascular
deaths was higher in XANAP compared with XANTUS (58.3% vs
41.5%). These results cannot be compared with those of the phase
III ROCKET AF study because XANAP, like other observational
studies, did not select patients based on strict inclusion criteria. In
contrast, phase III studies typically exclude patients with competing
co-morbidities, such as active cancer or short life expectancy. The
baseline characteristics of patients enrolled in these trials and the
follow-up periods were different; therefore, it is difficult to make
meaningful comparisons of mortality rates between such different
types of studies.
4.1 | Limitations
XANAP was a real-world, single-arm study and, as with any open-label
study, the study design can introduce bias related to knowledge about
treatment. Moreover, interference with patient management was not
allowed because of the non-interventional nature of the study. In par-
ticular, this resulted in a relatively high proportion of patients (48.5%)
with missing renal function data, similar to observations in the XAN-
TUS study (in which CrCl measurements were unavailable for 34.4%
of patients).9 Because of the observational nature of the study, it is
possible that CrCl was measured but not documented by the prescrib-
ing physician for some patients, which would have contributed to the
missing data. Additionally, because rivaroxaban prescription was at the
discretion of the treating physician, and a relatively important propor-
tion of CrCl data were missing, some patients may not have received
the label-recommended dose of rivaroxaban.
5 | CONCLUSIONS
XANAP is the first real-world, prospective, observational study to
describe rivaroxaban use in a broad patient population with NVAF in
10 countries of the Asia-Pacific region. XANAP had low rates of
stroke/non-CNS SE and major bleeding, including GI and fatal bleed-
ing. When taking differences in baseline risk factors into considera-
tion, findings were consistent with XANTUS and the phase III
ROCKET AF study and the subsequent subanalysis in East Asian
patients. This is particularly relevant in terms of CHADS2 and
CHA2DS2-VASc scores, which were similar to those in XANTUS, but
lower than those in the ROCKET AF East Asian subanalysis.
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